The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
IG

i.guerrero

TL2 · Lagos

Contributes reviews on supplier material. Based in Lagos.

Joined 18 April 2025 · last posted 9h

76Posts here
4Topics
0Solutions
750Likes received
435Likes given
23Badges
182Days visited
2.7kPosts read

Recent activity

Full stream
  • Adolescents: a distinct evidence base Replied, post #4 · Clinical › Special populations · 28 Jul 2026 · 25 likes Adolescent evidence exists for some compounds in this class and is a separate approval decision with its own trials rather than an extension of the adult data.
  • Reading a home test result without over-claiming Replied, post #137 · Analytics › Home & field testing · 27 Jul 2026 · 12 likes Where a home observation and an independent result disagree, the independent one is measuring something more specific. That does not make the home observation useless —…
  • What is genuinely unknown about long-term amylin agonism Replied, post #72 · Compounds › Cagrilintide & amylin analogues · 22 Jul 2026 · 2 likes On analysis: an amylin analogue and its aggregates are not equally detectable by a standard reversed-phase method, because a large aggregate may not elute at all. Area…
  • Coming back to: Why a preprint's supplementary material is often the best part Replied, post #89 · Evidence › Preprints · 26 Jun 2026 · 5 likes Post #88 answers the question as asked. The question underneath it is different. Version numbers on a preprint server matter. Citing version one of something now on…
  • A critique that turned out to be unfair, retracted by its author Replied, post #17 · Evidence › Study critique · 23 Jun 2026 · 0 likes On critique the community has more anecdote than the confidence in this thread implies, and I include my own contribution in that.
  • Primary endpoint hierarchies and why order matters — one year on Replied, post #20 · Evidence › Trials · 19 Jun 2026 · 1 like Post #19 is right about the mechanism and I think understates the practical bit. Two questions I would want answered before drawing anything from the Primary endpoint…
  • Injecting into an area that has become firm: why not to Replied, post #73 · Practice › Administration · 14 Jun 2026 · 7 likes Post #72 answers the question as asked. The question underneath it is different. Sharps disposal is the part of this that gets least attention and is genuinely a legal…
  • Coming back to: Time to steady state after a dose increase Replied, post #64 · Pharmacology › Pharmacokinetics · 29 May 2026 · 10 likes Renal clearance: these compounds are cleared partly via the kidney. In severe renal impairment, clearance is slowed and accumulation risk is higher. Dose adjustments…
  • Fasting versus non-fasting and which tests care Replied, post #34 · Clinical › Bloodwork · 23 May 2026 · 0 likes A request rather than an answer: could whoever has the primary source for fasting versus non-fasting post it? I have seen the claim three times this month and each…
  • A payment that went through twice: how it was resolved Replied, post #25 · Sourcing › Payments · 23 Apr 2026 · 3 likes Order confirmations that state the lot to be shipped are rare and are the single most useful thing a supplier can put on one.
  • Anaesthesia and elective surgery: the aspiration question Replied, post #89 · Practice › Interactions · 17 Apr 2026 · 31 likes The practical version of anaesthesia and elective surgery is three sentences long. The rigorous version is three pages and reaches the same conclusion with the…
  • [2026 update] Does a peptide degrade silently, with no visual change? Replied, post #42 · Practice › Storage & stability · 3 Apr 2026 · 24 likes Worth separating two things that post #38 runs together. What I want from this peptide thread is the list of things that would need to be true for the claim to hold. If…